Oasmia Pharmaceutical AB Announces Closing of U.S. Initial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing

New York, NY, 2015-10-29 08:30 CET (GLOBE NEWSWIRE) --  

NEW YORK, NY –October 29, 2015 – Oasmia Pharmaceutical AB (NASDAQ: OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology (“Oasmia” or the “Company”). Oasmia’s product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Oasmia announce the closing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia’s ordinary shares. The Company received gross proceeds of approximately $9,500,354 from the initial securities sold in this offering, before deducting underwriting discounts, commissions and other related expenses. The warrants have an exercise price of $4.06, are exercisable immediately and will expire ten years from the date of issuance. The Company granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and/or (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments. The underwriters have exercised an option to purchase 111,150 such additional warrants, which transaction closed on October 28, 2015. 

The ADSs began trading on The NASDAQ Capital Market under the symbol “OASM” on October 23, 2015. 

Proceeds from this offering will be used to fund: (i) new clinical trials and other regulatory requirements of Oasmia’s product and product candidates, (ii) production development, including validation batches, and (iii) other general corporate purposes, including employees, rent, and costs and expenses of being a U.S. public company.  

Rodman & Renshaw, a unit of H.C. Wainwright & Co. and Joseph Gunnar & Co., LLC acted as joint book-running managers in this offering. 

The securities described herein were sold pursuant to a registration statement on Form F-1 relating to this offering filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC as of October 22, 2015. The offering of these securities will be made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the offering may be obtained from Oasmia, with an address of Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: info@oasmia.com. In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.oasmia.com.  In addition, you may contact Rodman & Renshaw, a unit of H.C. Wainwright & Co., 430 Park Avenue, 4th Floor, New York, NY 10022, email: placements@hcwco.com and Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: prospectus@jgunnar.com. 

Sichenzia Ross Friedman & Ference LLP acted as U.S. legal counsel to Oasmia, and McGuireWoods LLP acted as legal counsel to the underwriters. 

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.  

About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365). 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Oasmia’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Oasmia does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on October 21, 2015 and future reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

         Julian Aleksov, Executive Chairman,          Tel: +46 18 50 54 40          E-mail: julian.aleksov@oasmia.com                    Anders Lundin, Chief Financial Officer          Mobile: +46 70 20 96 300          E-mail: anders.lundin@oasmia.com                    Eric Fischgrund          FischTank Marketing and PR          E-mail: eric@fischtankpr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 181

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review Lawsuit Against Cepton, Inc. (CPTN)

Updated Category News Views 203

Class Action Against Cepton, Inc. Unveiled Recent developments have raised significant concerns for investors of Cepton, Inc. (NASDAQ: CPTN) following revelations of a class action lawsuit. Leading national plaintiffs' law firm Berger Montague has stepped in to help those impacted. The lawsuit focuses on investors who bought or sold Cepton shares during a specified...

Continue Reading
Exploring Uber Technologies: A Strategic Trade Perspective

Updated Category News Views 172

Uber Technologies Inc.'s Current Market Position Recently, ride-sharing giant Uber Technologies, Inc. (NYSE: UBER) experienced a notable increase in its market value. This uplift followed an innovative announcement regarding the capability for riders to book an Avride robotaxi, showcasing the evolution of autonomous mobility solutions. In the past five trading days, UBER...

Continue Reading
Celebrating Diversity: Winners of the Art Limitless Contest

Updated Category News Views 168

Celebrating the Art Limitless Competition Winners In the heart of artistic innovation, BE OPEN has unveiled the winners of the Art Limitless competition, an initiative celebrating inclusivity and diversity in the arts. This remarkable program strives to empower artists with disabilities, showcasing their work while inspiring broader societal awareness. What is Art...

Continue Reading
Certuity Welcomes Constantine Hatzivassiliou as New Partner

Updated Category News Views 246

Certuity Welcomes Constantine Hatzivassiliou as New Partner Certuity, a leading multi-family office dedicated to serving high-net-worth individuals and families, is thrilled to announce the promotion of Managing Director Constantine Hatzivassiliou to Partner. This significant advancement not only reflects Hatzivassiliou's commitment to the firm but also the invaluable...

Continue Reading
Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings

Updated Category News Views 124

Sila Realty Trust, Inc. Announces Upcoming Q3 Earnings Release Sila Realty Trust, Inc. (NYSE: SILA) recently made an announcement regarding its anticipated financial results for the third quarter of 2024. The company will release these earnings on a Tuesday morning, just before the market opens. This timely communication reflects Sila's commitment to transparency and...

Continue Reading